These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 15556908)

  • 21. Duloxetine as adjunctive treatment to clozapine in patients with schizophrenia: a randomized, placebo-controlled trial.
    Mico' U; Bruno A; Pandolfo G; Maria Romeo V; Mallamace D; D'Arrigo C; Spina E; Zoccali RA; Muscatello MR
    Int Clin Psychopharmacol; 2011 Nov; 26(6):303-10. PubMed ID: 21934625
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful treatment of refractory hypochondriasis with duloxetine.
    Politi P; Emanuele E
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1145-6. PubMed ID: 17493731
    [No Abstract]   [Full Text] [Related]  

  • 23. Duloxetine and other antidepressants in the treatment of patients with fibromyalgia.
    Arnold LM
    Pain Med; 2007 Sep; 8 Suppl 2():S63-74. PubMed ID: 17714117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between TSH levels in the normal range and short-term duloxetine efficacy.
    Corruble E; Goldberger C; Spann M
    J Affect Disord; 2010 Jun; 123(1-3):312-6. PubMed ID: 19825504
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immediate switching from moclobemide to duloxetine may induce serotonin syndrome.
    Jimenez-Genchi A
    J Clin Psychiatry; 2006 Nov; 67(11):1821-2. PubMed ID: 17196070
    [No Abstract]   [Full Text] [Related]  

  • 26. Duloxetine: a review of its pharmacology and use in chronic pain management.
    Bellingham GA; Peng PW
    Reg Anesth Pain Med; 2010; 35(3):294-303. PubMed ID: 20921842
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Duloxetine is effective in treating depression in multiple sclerosis patients: an open-label multicenter study.
    Solaro C; Bergamaschi R; Rezzani C; Mueller M; Trabucco E; Bargiggia V; Dematteis F; Mattioda A; Cimino V; Restivo D; Patti F; Cavalla P
    Clin Neuropharmacol; 2013; 36(4):114-6. PubMed ID: 23783007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biological perspectives. Serotonin and norepinephrine reuptake inhibitors (SNRIs): venlafaxine and duloxetine.
    Lee SI; Keltner NL
    Perspect Psychiatr Care; 2006 May; 42(2):144-8. PubMed ID: 16677140
    [No Abstract]   [Full Text] [Related]  

  • 29. Duloxetine in major depressed patients resistant to SSRIs and/or venlafaxine.
    Pitchot W; Scantamburlo G; Ansseau M
    Psychiatr Danub; 2010 Nov; 22 Suppl 1():S106-7. PubMed ID: 21057413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Duloxetine: a new selective and dual-acting antidepressant.
    Bauer M; Möller HJ; Schneider E
    Expert Opin Pharmacother; 2006 Mar; 7(4):421-7. PubMed ID: 16503814
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Duloxetine treatment of Premenstrual Dysphoric Disorder: case reports.
    Ramos MG; Hara C; Rocha FL
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):579-80. PubMed ID: 17897763
    [No Abstract]   [Full Text] [Related]  

  • 32. Duloxetine related hypersexuality: a case report.
    Lai CH
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Mar; 34(2):414-5. PubMed ID: 19945494
    [No Abstract]   [Full Text] [Related]  

  • 33. Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder.
    Delgado PL; Brannan SK; Mallinckrodt CH; Tran PV; McNamara RK; Wang F; Watkin JG; Detke MJ
    J Clin Psychiatry; 2005 Jun; 66(6):686-92. PubMed ID: 15960560
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prescribing update: why choose duloxetine for depression?
    Tobin ML
    Issues Ment Health Nurs; 2007 Jan; 28(1):117-20. PubMed ID: 17130011
    [No Abstract]   [Full Text] [Related]  

  • 35. [Physical recovery is part of remission].
    Krankenpfl J; 2004; 42(3-4):110. PubMed ID: 15311907
    [No Abstract]   [Full Text] [Related]  

  • 36. A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder.
    Allgulander C; Nutt D; Detke M; Erickson J; Spann M; Walker D; Ball S; Russell J
    J Psychopharmacol; 2008 Jun; 22(4):417-25. PubMed ID: 18635722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful treatment with duloxetine in a case of treatment refractory bulimia nervosa: a case report.
    Hazen E; Fava M
    J Psychopharmacol; 2006 Sep; 20(5):723-4. PubMed ID: 16401659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled trial.
    Alaka KJ; Noble W; Montejo A; Dueñas H; Munshi A; Strawn JR; Lenox-Smith A; Ahl J; Bidzan L; Dorn B; Ball S
    Int J Geriatr Psychiatry; 2014 Sep; 29(9):978-86. PubMed ID: 24644106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical impact of duloxetine treatment on sleep in patients with major depressive disorder.
    Brecht S; Kajdasz D; Ball S; Thase ME
    Int Clin Psychopharmacol; 2008 Nov; 23(6):317-24. PubMed ID: 18854719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Duloxetine-induced cutaneous adverse reaction.
    Oulis P; Masdrakis VG; Karakatsanis NA; Karapoulios E; Kouzoupis AV; Soldatos CR
    J Clin Psychopharmacol; 2008 Feb; 28(1):104-5. PubMed ID: 18204353
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.